WMS 2022 poster: Safety and efficacy of ataluren in nmDMD patients from Study 041, a phase 3 placebo-controlled trial
This poster, presented at WMS 2022, focuses on the safety and efficacy results of Study 041, a phase 3 placebo-controlled trial of ataluren for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
Review the demographics of participants in Study 041 – for the intention to treat population and key subgroups
Find out about the efficacy of ataluren for patients with nmDMD
Learn about the safety of ataluren for patients with nmDMD
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at email@example.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This poster was developed and funded by PTC Therapeutics for WMS 2022.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300003 | February 2023
Sign in or register to access exclusive content on this site